<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03704285</url>
  </required_header>
  <id_info>
    <org_study_id>171215006</org_study_id>
    <nct_id>NCT03704285</nct_id>
  </id_info>
  <brief_title>Development of pk/pd Model of Propofol in Patients With Severe Burns</brief_title>
  <acronym>HUAPQ</acronym>
  <official_title>Development of Pharmacokinetic / Pharmacodynamic (pk/pd) Model of Propofol in Patients With Severe Burns</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Victor Contreras, MSN</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pontificia Universidad Catolica de Chile</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Burn injuries are a prevalent problem. Actually, in Chile the Ministry of Health has recorded
      6435 hospital burns and has reported 569 deaths from this cause. The specific mortality rate
      for burning in Chile was 4.5 per 100,000 inhabitants per year. Survival in extensive burns
      has progressively improved, thanks to advances in understanding the pathophysiology of the
      burn and its more aggressive treatment. This requires effective prehospital treatment,
      transportation, resuscitation, support of vital functions and repair of the skin cover.

      Much of the procedures performed in large burns require general anesthesia. Being Total
      Intravenous Anesthesia (TIVA) with propofol an alternative that would have advantages over
      inhalational anesthesia, as a decrease in postoperative nausea and vomiting and produce less
      environmental pollution 3 and the antihyperalgesic effect of propofol. Within TIVA - Target
      Control Infusion (TCI) - uses infusion systems that incorporate PK-PD models for predict the
      dose of drug required to reach a certain concentration in the target organ.

      The formulation of a PK model that considers the variables of this group of patients, such
      as: degree of injury, inflammatory state and compromised body surface; associated with
      general variables such as: age, weight and nutrition, it would allow to reduce the predictive
      error in this population, thus improving the dosing of these patients when using TCI.

      Given the lack evidence on the PK-PD of propofol is this group of patients burned, has led to
      raise the development of this study that seeks to develop a PK-PD model that fits them.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be invited to participate before surgery, the inclusion criteria will be
      revised and the informed consent will be signed.

      In the operating room will be recorded demographic data and relevant background such as: Age,
      Weight, Size, BMI, Lean Mass, Fat Mass and Total body water among others.

      Afterwards, in the operating room, the patient will be monitored regularly: ECG (DII) if
      feasible and pulse oximetry. An arterial catheter will be installed for monitoring and taking
      blood samples during the intraoperative period.

      In addition, the EEG will be monitored through a frontal electroencephalographic monitoring
      (BIS) system; that will be recorded throughout the surgery.

      The anesthetic induction will be with propofol and remifentanil. The propofol will be
      administered using an initial bolus of 1-2 mg / kg according to the criteria of the
      anesthetist and then a continuous infusion of 10 mg / kg / hr that will be adjusted adjusted
      to maintain a BIS between 40 and 60.

      Plasma samples of propofol: arterial samples of 3-4 ml will be taken at 2, 5, 10, 30, 60
      and/or 120 min after beginning the administration of propofol. Subsequently samples will be
      taken at 0, 5, 15, 30, 60, 120, 240 min and at 6-12 hrs after stopping the infusion of
      propofol. The samples will be centrifuged and stored at -20 ° C until analysis by HPLC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Propofol plasmatic levels Measured by high pressure liquid chromatography</measure>
    <time_frame>From start of propofol infusion to 12 hrs after stopped infusion of propofol.</time_frame>
    <description>Propofol total dose. 2, 5, 10, 30, 60 and 120 min after induction with propofol. Subsequently, samples will be taken at 0, 5, 15, 30, 60, 120, 240 min and at 6-12 hrs after stopping infusion of propofol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemodynamics</measure>
    <time_frame>Every 5 min. Since entering operating room up to end of anesthesia and leaving to recovery room. In average 2 hrs.</time_frame>
    <description>Arterial pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Every 5 min. Since entering operating room up to end of anesthesia and leaving to recovery room. In average 2 hrs.</time_frame>
    <description>Heart rate (bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse oximetry</measure>
    <time_frame>Every 5 min. Since entering operating room up to end of anesthesia and leaving to recovery room. In average 2 hrs.</time_frame>
    <description>% oximetry saturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BIS</measure>
    <time_frame>Every 5 min. Since entering operating room up to end of anesthesia and leaving to recovery room. In average 2 hrs.</time_frame>
    <description>Depth of anesthesia will be recorded with BIS monitor. From 60 - 40</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Anesthesia</condition>
  <condition>Burned</condition>
  <condition>Operative Wound</condition>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <description>Severe burn adult under general anesthesia with propofol + remifentanil evaluation of propofol effect using BIS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Patients undergoing general anesthesia using target controlled infusion of propofol. Initial bolus of 1-2 mg/kg and then a continuous infusion of 10 mg/kg/hr that will be adjusted adjusted to maintain a BIS between 40 and 60.</description>
    <arm_group_label>Propofol</arm_group_label>
    <other_name>Propofol Intravenous dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BIS</intervention_name>
    <description>GeneralAnesthesia maintenance with propofol+remifentanil guided by BIS monitoring.</description>
    <arm_group_label>Propofol</arm_group_label>
    <other_name>General anesthetic</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with Major burns
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe burns with life risk that require treatment in Burn Units and / or Critical
             Patient Units.

          -  In spontaneous ventilation

          -  SAS 4

        Exclusion Criteria:

          -  Electric burns

          -  ASA IV o V

          -  Inability to install BIS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis I Cortinez, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pontificia Universidad Catolica de Chile</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>VICTOR E CONTRERAS, MSN</last_name>
    <phone>56223549217</phone>
    <email>vecontre@uc.cl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcela A Avila, MD</last_name>
    <phone>56988376943</phone>
    <email>maravila7@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Victor Contreras</name>
      <address>
        <city>Santiago</city>
        <state>Región Metropolitana</state>
        <zip>8420525</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VICTOR CONTRERAS, MSN</last_name>
      <phone>56223549217</phone>
      <email>vecontre@uc.cl</email>
    </contact>
    <contact_backup>
      <last_name>Marcela Avila, MD</last_name>
      <phone>56988376943</phone>
      <email>maravila7@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Luis I Cortinez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcela A Avila, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <reference>
    <citation>Shin SW, Cho AR, Lee HJ, Kim HJ, Byeon GJ, Yoon JW, Kim KH, Kwon JY. Maintenance anaesthetics during remifentanil-based anaesthesia might affect postoperative pain control after breast cancer surgery. Br J Anaesth. 2010 Nov;105(5):661-7. doi: 10.1093/bja/aeq257. Epub 2010 Sep 28.</citation>
    <PMID>20876698</PMID>
  </reference>
  <reference>
    <citation>Cortínez LI, De la Fuente N, Eleveld DJ, Oliveros A, Crovari F, Sepulveda P, Ibacache M, Solari S. Performance of propofol target-controlled infusion models in the obese: pharmacokinetic and pharmacodynamic analysis. Anesth Analg. 2014 Aug;119(2):302-10. doi: 10.1213/ANE.0000000000000317.</citation>
    <PMID>24977639</PMID>
  </reference>
  <reference>
    <citation>Cortínez LI, Anderson BJ, Penna A, Olivares L, Muñoz HR, Holford NH, Struys MM, Sepulveda P. Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. Br J Anaesth. 2010 Oct;105(4):448-56. doi: 10.1093/bja/aeq195. Epub 2010 Aug 14.</citation>
    <PMID>20710020</PMID>
  </reference>
  <reference>
    <citation>Eleveld DJ, Colin P, Absalom AR, Struys MMRF. Pharmacokinetic-pharmacodynamic model for propofol for broad application in anaesthesia and sedation. Br J Anaesth. 2018 May;120(5):942-959. doi: 10.1016/j.bja.2018.01.018. Epub 2018 Mar 12. Erratum in: Br J Anaesth. 2018 Aug;121(2):519.</citation>
    <PMID>29661412</PMID>
  </reference>
  <reference>
    <citation>Rolle A, Paredes S, Cortínez LI, Anderson BJ, Quezada N, Solari S, Allende F, Torres J, Cabrera D, Contreras V, Carmona J, Ramírez C, Oliveros AM, Ibacache M. Dexmedetomidine metabolic clearance is not affected by fat mass in obese patients. Br J Anaesth. 2018 May;120(5):969-977. doi: 10.1016/j.bja.2018.01.040. Epub 2018 Mar 28.</citation>
    <PMID>29661414</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 3, 2018</study_first_submitted>
  <study_first_submitted_qc>October 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2018</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Pontificia Universidad Catolica de Chile</investigator_affiliation>
    <investigator_full_name>Victor Contreras, MSN</investigator_full_name>
    <investigator_title>Co-Investigator. Project Manager of Department of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>anesthesia</keyword>
  <keyword>burned</keyword>
  <keyword>TIVA</keyword>
  <keyword>propofol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Anesthetics, General</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

